ZA981478B - Use of interleukin-15 - Google Patents

Use of interleukin-15

Info

Publication number
ZA981478B
ZA981478B ZA981478A ZA981478A ZA981478B ZA 981478 B ZA981478 B ZA 981478B ZA 981478 A ZA981478 A ZA 981478A ZA 981478 A ZA981478 A ZA 981478A ZA 981478 B ZA981478 B ZA 981478B
Authority
ZA
South Africa
Prior art keywords
antibodies
alpha
inhibiting
compounds
receptor
Prior art date
Application number
ZA981478A
Other languages
English (en)
Inventor
Johan Adriaan Marc Grooten
Hans Peter Raf Dooms
Walter Charles Fiers
Original Assignee
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA981478(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Interuniv Inst Biotech filed Critical Vlaams Interuniv Inst Biotech
Publication of ZA981478B publication Critical patent/ZA981478B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA981478A 1997-02-21 1998-02-23 Use of interleukin-15 ZA981478B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97200515 1997-02-21

Publications (1)

Publication Number Publication Date
ZA981478B true ZA981478B (en) 1998-08-24

Family

ID=8228040

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA981478A ZA981478B (en) 1997-02-21 1998-02-23 Use of interleukin-15

Country Status (9)

Country Link
US (3) US6344192B1 (fr)
EP (2) EP0971728B1 (fr)
AT (2) ATE295736T1 (fr)
AU (1) AU6726698A (fr)
DE (2) DE69810091T2 (fr)
DK (1) DK1273304T4 (fr)
ES (1) ES2187946T3 (fr)
WO (1) WO1998036768A1 (fr)
ZA (1) ZA981478B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192935B1 (en) 1993-03-08 2007-03-20 Amgen Inc. Polynucleotides encoding epithelium-derived T-cell factor and uses thereof
IL126919A0 (en) * 1998-11-05 1999-09-22 Univ Ben Gurion Antisense oligomer
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
EP1927657A3 (fr) * 2000-05-11 2008-10-22 Baylor Research Institute Compositions et procédés pour la production de cellules présentant un antigène
EP1349873B1 (fr) 2000-09-14 2009-04-01 Beth Israel Deaconess Medical Center, Inc. Modulation de reactions de cellules t induites par il-15 et il-2
US7041302B2 (en) * 2001-01-09 2006-05-09 Biother Corporation Therapeutic modulation of the tumor inflammatory response
EP1425389B1 (fr) 2001-08-23 2011-11-02 Genmab A/S Anticorps humains specifiques diriges contre l'interleukine 15 (il-15)
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
ATE438662T1 (de) 2003-03-26 2009-08-15 Apogenix Gmbh Verbesserte fc-fusionsproteine
CA2531773A1 (fr) 2003-07-21 2005-02-17 Transgene S.A. Nouvelles cytokines multifonctionnelles
CU23472A1 (es) * 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
EP1809321B1 (fr) 2004-10-08 2012-03-14 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Immunotherapie adoptive avec survie amelioree de lymphocytes t
PL1899364T3 (pl) 2005-05-17 2020-08-24 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
EP1777294A1 (fr) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
JP5709356B2 (ja) 2006-01-13 2015-04-30 アメリカ合衆国 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
CA3028038C (fr) 2007-05-11 2021-08-10 Altor Bioscience Corporation Molecules de fusion et variants d'il-15
NZ582330A (en) 2007-06-27 2012-05-25 Marinepolymer Tech Inc COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
AU2010282280B2 (en) 2009-08-14 2016-06-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymic output and to treat lymphopenia
PT2619229T (pt) 2010-09-21 2016-07-13 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
ES2841983T3 (es) 2011-03-23 2021-07-12 Hutchinson Fred Cancer Res Método y composiciones para inmunoterapia celular
ES2906615T3 (es) 2013-04-19 2022-04-19 Cytune Pharma Tratamiento derivado de citocinas con síndrome de fuga vascular reducido
KR20230028807A (ko) 2014-06-30 2023-03-02 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
BR112019007920A2 (pt) 2016-10-21 2019-10-08 Altor Bioscience Corp moléculas multiméricas à base de il-15
WO2023086772A1 (fr) 2021-11-12 2023-05-19 Xencor, Inc. Anticorps bispécifiques se liant à b7h3 et à nkg2d
WO2024102636A1 (fr) 2022-11-07 2024-05-16 Xencor, Inc. Anticorps bispécifiques qui se lient à b7h3 et mica/b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5591630A (en) * 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
CA2205430C (fr) * 1994-11-17 2001-09-04 University Of South Florida Procede de fabrication d'un medicament destine au traitement de l'immunodeficience secondaire
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
CN1200037A (zh) * 1995-10-17 1998-11-25 韦恩州立大学 鸡白细胞介素－15及其用途
US5870759A (en) * 1996-10-09 1999-02-09 Oracle Corporation System for synchronizing data between computers using a before-image of data
US6065018A (en) * 1998-03-04 2000-05-16 International Business Machines Corporation Synchronizing recovery log having time stamp to a remote site for disaster recovery of a primary database having related hierarchial and relational databases
US6356917B1 (en) * 1998-07-17 2002-03-12 Ncr Corporation Monitoring and raising alerts for database jobs
US6553392B1 (en) * 1999-02-04 2003-04-22 Hewlett-Packard Development Company, L.P. System and method for purging database update image files after completion of associated transactions
US6728879B1 (en) * 1999-06-02 2004-04-27 Microsoft Corporation Transactional log with multi-sector log block validation

Also Published As

Publication number Publication date
DK1273304T3 (da) 2005-09-12
WO1998036768A1 (fr) 1998-08-27
ATE295736T1 (de) 2005-06-15
ATE229342T1 (de) 2002-12-15
DE69810091D1 (de) 2003-01-23
EP1273304B2 (fr) 2009-07-15
DE69830257D1 (de) 2005-06-23
US20070134718A1 (en) 2007-06-14
DE69830257T2 (de) 2006-02-02
AU6726698A (en) 1998-09-09
EP1273304A3 (fr) 2003-04-23
ES2187946T3 (es) 2003-06-16
EP1273304A2 (fr) 2003-01-08
EP0971728B1 (fr) 2002-12-11
EP0971728A1 (fr) 2000-01-19
DE69810091T2 (de) 2003-10-09
US6344192B1 (en) 2002-02-05
DE69830257T3 (de) 2009-10-15
DK1273304T4 (da) 2009-08-31
EP1273304B1 (fr) 2005-05-18
US20020182178A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
ZA981478B (en) Use of interleukin-15
AU1332099A (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
RS20130234A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody
EP1260521A3 (fr) Variantes d'immunoglobulines pour des récepteurs Fc-epsilon spécifiques
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
MX9707021A (es) Receptor de il-7.
CA2172376A1 (fr) Anticorps diriges contre le cd40
IL142905A0 (en) Functional antagonists of hedgehog activity
EP0334165A3 (en) Monoclonal antibodies
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
NZ296265A (en) Receptors able to specifically bind to a bacillus thuringiensis (bt) toxin; recombinant expression systems including the receptors for host cells; use as pesticides and in chemotherapy
PT939809E (pt) Ligandos do receptor de tie-2 (ligando 3 de tie e ligando 4 de tie) e suas utilizacoes
EP0770624A3 (fr) Peptide pouvant induire une réponse immune contre le cancer de l'estomac et agent contenant ce peptide pour la prévention ou le traitement du cancer de l'estomac
AU4157501A (en) Her-2 binding antagonists
ES2129120T3 (es) Un receptor de celulas t humanas de la familia de receptores acoplados a la proteina g.
CA2038578A1 (fr) Diffusion des agents
GB9416536D0 (en) Orphan receptor
IL86710A0 (en) Polypeptide receptor for interleukin-2,antibodies against this polypeptide and pharmaceutical compositions containing the same
NZ237533A (en) Monoclonal antibodies which bind to oncostatin m, cell lines producing them
MX9704225A (es) Fragmentos de anticuerpos monoclonales que tienen actividad inmunosupresora.
SI1027375T1 (sl) Anti-idiotipska monoklonska protitelesa, njihova uporaba v aktivni imunoterapiji malignih tumorjev in sestavki, ki jih vsebujejo
MX9705082A (es) Composiciones para el suministro de antigenos.